199114-26-6

Basic information

• Product Name: 4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzaldehyde
• Synonyms: 4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzaldehyde
• CAS NO: 199114-26-6
• Molecular Weight: 286.331
• Mol File: 199114-26-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzaldehyde(199114-26-6)
• EPA Substance Registry System: 4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzaldehyde(199114-26-6)

Safety Data

• Hazardous Substances Data: 199114-26-6(Hazardous Substances Data)

Upstream product

• 16858-50-7 2-ethyl-6-methyl-4(3H)pyrimidone 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 

Downstream Products

• 199113-79-6 5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]phenylmethylene]thiazolidine-2,4-dione 
• 199114-53-9 5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]phenylmethylene]-2-thioxo-1,3-oxazolidine-4-one 
• 199113-95-6 PMT₁₃ 
• 199114-42-6 N-{4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzyl}-N-hydroxyurea 
• 199114-41-5 4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzyl hydroxyl amine 
• 199114-40-4 4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzaldehyde oxime 

Relevant articles and documents

Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives

A series of pyrimidinone derivatives of thiazolidinediones were synthesized. Their biological activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPARγ transactivation assay was performed in HEK 293T cells. PMT13 showed the best biological activity in this series. PMT13 (5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy] phenylmethyl]thiazolidine-2,4-dione) showed better plasma glucose, triglyceride and insulin-lowering activity in db/db mice than rosiglitazone and pioglitazone. PMT13 showed better PPARγ transactivation than the standard compounds. Pharmacokinetic study in Wistar rats showed good systemic exposure of PMT13. Twenty-eight day oral toxicity study in Wistar rats did not show any treatment-related adverse effects.

Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically accep